Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR.
Michalczyk, A., Kluter, S., Rode, H.B., Simard, J.R., Grutter, C., Rabiller, M., Rauh, D.(2008) Bioorg Med Chem 16: 3482-3488
- PubMed: 18316192 
- DOI: 10.1016/j.bmc.2008.02.053
- Primary Citation of Related Structures:  
2QI8, 2QLQ, 2QQ7 - PubMed Abstract: 
Resistance to kinase-targeted cancer drugs has recently been linked to a single point mutation in the ATP binding site of the kinase. In EGFR, the crucial Thr790 gatekeeper residue is mutated to a Met and prevents reversible ATP competitive inhibitors from binding ...